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The ITEQ comprises 28 items with the subscales ‘leisure activi-
ties’ (4 items), ‘psychological barriers’ (2 items), ‘handling’ (5
items), ‘diabetes control’ (6 items), ‘dependence’ (5 items),
‘weight control’ (3 items), ‘sleep’ (2 items) as well as one item
assessing general TS. First results demonstrated good psychome-
tric properties. The aim of the present paper was to compare the
performance of the ITEQ and DTSQ in discriminating patients
TS in different insulin therapies. METHODS: A sample of
T2DM patients (n = 150) completed the ITEQ and DTSQ. TS as
assessed by the instruments was compared between respondents
with different insulin regimens (intensiﬁed insulin therapy,
n = 70; OAD plus insulin, n = 47; longacting insulin only, n = 33)
using analysis of variance (ANOVA). RESULTS: While ITEQ
subscales (diabetes control, dependence, weight control, sleep)
and the total score revealed signiﬁcant differences in patients TS
between therapy regimens (p < 0.001), results for the DTSQ
score were only marginally signiﬁcant (p = 0.154). Furthermore
different patterns for ITEQ subscales were observed even for
variants of insulin therapy within one type of regimen. CON-
CLUSION: Comparisons with an existing measurement suggest
that the ITEQ performs well in discriminating TS levels in
patients undergoing diabetes treatment. The content of the ITEQ
subscales provide important information about speciﬁc aspects
of patients TS in insulin treatment. In the near future, the ITEQ
will be translated into other languages.
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OBJECTIVES: As an aid to diabetes clinical care and research we
sought to develop a valid and reliable instrument: the Diabetes
Medication Satisfaction Tool (DMSAT) to measure patient sat-
isfaction with a broad spectrum of diabetes treatment regimens
in primary care. This was a cross-sectional survey study to
develop and test a self-report questionnaire on satisfaction with
diabetes medications. METHODS: Item content was obtained
from focus groups of patients attending community health
clinics, pre-tested in a sample of 55 patients with Type 2 diabetes,
and examined in a sample of 140 patients of a group family
practice with a diagnosis of diabetes and prescribed medical
therapy. Factor analysis and tests of subscale and total score
means across clinical groups were used to examine measurement
characteristics. RESULTS: Sixteen items were retained assessing
four distinct medication treatment experiences: ease and conve-
nience, lifestyle burdens, well-being, and medical control. Con-
struct validity of the scales and total score were demonstrated by
statistically signiﬁcant (p < 0.05) associations with treatment
complexity, follow-up visits, self-rated glucose control, health
worries, and A1c in the last six months. Internal consistency
reliability coefﬁcients for the scales and total score ranged from
0.89 to 0.95. CONCLUSION: The results of this study suggest
that the DMSAT has good construct validity and reliability, and
is sensitive to levels of clinical and patient reported outcomes that
relate to treatment burden and Type II diabetes control. The
DMSAT offers a comprehensive assessment of the patient accept-
ability and satisfaction with the use of diabetes medication
therapy in their daily life. Testing across two independent patient
samples showed DMSAT scores correspond to clinically relevant
outcomes.
ENDOCRINE DISORDERS—Methods and Concepts
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OBJECTIVES: To compare the number of steps, associated time
and costs related to administration of human growth hormone
(hGH) via different devices using time-and-motion simulations.
Previously all hGH formulations required reconstitution of lyo-
philized powder and transfer to syringe prior to administration.
With the development of a liquid formulation of hGH, premixed
and preﬁlled disposable devices are now available. Daily compli-
ance may depend upon “ease of use” characteristics across
various product and device combinations. Also, the additional
time required to prepare devices which are not available with
premixed product may result in increased costs from professional
and patient perspectives. METHODS: It is assumed the users
attend 1 training session, prepare 1 preparation per week, and
administer the drug three or seven times per week depending on
the product labeling speciﬁcations. This study simulates 3 phases:
Learning (initial instructions for use), Preparation (opening a
new package and making the device ready for use), and Admin-
istration (the actual injection of either the ﬁrst dose or subse-
quent doses). Nurses without prior experience with the
application of hGH or similar drug-device combinations are,
after the initial training session, running 5 series of preparations,
initial administrations, and follow-up dose administrations to
reﬂect the learning curves in the respective steps. Costs will
include wages (Bureau of Labor Statistics) and drugs (First Data-
bank). RESULTS: This study design provides a unique method to
compare the learning curves for the different product/device com-
binations, and to compare the relative time needed for prepara-
tion and administration. The validated methods and preliminary
results will be part of the presentation. CONCLUSION: This
time and motion study protocol, allows for comparing the
number of steps and the overall time required for preparation
and application of hGH in various devices and can be applied to
self injectable product comparisons in general.
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OBJECTIVES: Through a literature review, evaluate the inci-
dence rates of different adverse events associated with blood
transfusions among the general population. METHODS: A
structured, 2-phase literature review was conducted using the
PubMed (National Library of Medicine) database to search for
articles quoting incidence rates of adverse reactions associated
with blood transfusions. The ﬁrst phase of the literature review
looked for general blood transfusion risk studies reported during
the time period of 1985 to 2007 to identify adverse events
associated with blood transfusions. The second phase of the
literature review, looking at studies reported 2000 to 2007,
assessed incidence rates for each adverse event identiﬁed during
the ﬁrst phase. The search generated 41 articles from which data
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were extracted and summarized. RESULTS: The study identi-
ﬁed 16 adverse events associated with blood transfusions in
which incidence rates were reported in the literature for the
time period of 2000 to 2007. Of those, the adverse events with
the highest associated mortality rate were: 1) acute haemolytic
transfusion reactions due to non-ABO compatibility (between
2.11%–7.06%); 2) transfusion-related acute lung injuries
(TRALI) (10% approx); and 3) bacterial sepsis (between 17%–
22%). Reported as incidence rates, the most frequently
reported adverse event was febrile reaction (0.9/1000 by trans-
fusion units) and mild allergic reaction (1/50–1/100 by trans-
fusion units). CONCLUSION: In spite of today’s safety and
quality controls measures for blood transfusions, a considerable
risk of adverse events is still associated with them. Therefore,
alternatives to blood transfusions should be considered when
possible.
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OBJECTIVES: IDA, the most common form of anaemia, has a
relatively high prevalence across Europe. IDA is common in
pregnancy, postpartum and inﬂammatory bowel disease (IBD)
with IDA prevalences of 18, 17 and 33% respectively. At
present, treatment with parenteral iron substitution is limited
by the amount of iron which can be administered intravenously
in any one application. This study estimates the BI associated
with partially substituting the standard i.v. treatment, iron
sucrose, with a new treatment, ferric carboxymaltose, allowing
for the application of higher dosages in a shorter time. The
study adopted the perspective of the Swiss mandatory health
insurance over 3 years covering the indications pregnancy, post-
partum and IBD. METHODS: Resource use was based on
primary data and guidelines. Costs were estimated using a fee-
for-service reimbursement system (Tarmed), including drug, per-
sonnel and other costs. The price of ferric carboxymaltose was
assumed to be that of iron sucrose +40%. The BI was estimated
for the ﬁrst 3 years post-launch, using a substitution rate of
20% in year 1 and 50% in year 2 and 3. RESULTS: Ferric
carboxymaltose reduces the costs per treatment cycle and
patient in IBD by 35% compared to iron sucrose (CHF 475 vs.
CHF 732), due to reduced personnel costs: 1000 mg iron
requires one application with ferric carboxymaltose and 5 for
iron sucrose (200 mg each). Total savings to the Swiss manda-
tory health insurance amount to approx. CHF 1 Mio (approx.
€ 611′600) in year 1 and approx. CHF 2.5 Mio in year 2 and
3 each. Costs were also reduced by 33% in the gynaecological
indication using smaller, empirical dosages of 500 mg. CON-
CLUSION: Treating IDA involves substantial costs to the Swiss
mandatory health insurance. Substitution of iron sucrose by
ferric carboxymaltose may help to reduce these due to saved
personnel costs, despite higher product costs.
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OBJECTIVES: To analyze cost-effectiveness of bortezomib
versus dexamethasone for recurrent or treatment-resistant mul-
tiple myeloma in Russian health care system. METHODS: The
study was performed from the Russian reimbursement system
point of view. An economic model prepared for the submission to
National Institute of Health and Clinical Excellence was used as
a framework. Effect of studied drugs was measured in life-years
gained. The effectiveness was estimated on the basis of APEX
study results and complemented with prognosis of long-term
outcomes. Direct medical costs for medication were included into
the model, registered prices were taken from the Russian reim-
bursement list while dose regimen and number of treatment
courses were considered to be equal to those used in APEX study.
The incremental cost-effectiveness ratio (CER) was calculated.
RESULTS: The incremental effectiveness of bortezomib versus
dexamethasone was estimated as 2,371–2,739 life-years gained
(the interval includes minimal and maximal values identiﬁed by
different approaches to long-term outcomes projection). The
incremental cost was 1 822 774,00 rubles (about 70 thousands
USD). The incremental CER was 67,510,148 — 792,510,43
rubles (25–29 thousands USD) per life-year gained. CONCLU-
SION: The incremental CER for bortezomib is comparable with
other expensive drugs included into the reimbursement system.
Further studies are needed to assess cost-effectiveness of bort-
ezomib vs other therapeutic strategies used for resistant and
recurrent multiple myeloma and to evaluate effectiveness in
medical practice.
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OBJECTIVES: To analyze cost-effectiveness of Ferrum Lek
(Ferrum III) versus Fenuls (Ferrum II) for iron-deﬁcient anemia in
elderly patients with gastrointestinal comorbidy in Russian
health care system. METHODS: Randomized multi-center
study of 132 ambulatory patients (60–86 years old, mean age
69.11  6.39; 102 (77.27%) were females). Criteria for anemia
was decreasing of hemoglobin (Hb) level below 110 g/L. Sixty-
six patients received either Ferrum Lek (200 mg daily) or Fenuls
(200 mg daily). Duration of treatment was 6 weeks. Criteria of
effectiveness were: normalization of Hb level; increasing levels
of Hb and Fe in plasma; adverse effects at day 42 after start
of treatment. The cost-effectiveness ratio (CER) was calculated
(cost of 1 g/L Hb increasing). RESULTS: At follow-up Hb level
increases in Ferrum Lek group was 30.1 g/L (12.3–88.4) and
19.8 g/L (4–39) in Fenuls group. Normalization of Hb level
(110 g/L) was achieved in 62 (93.94%) patients in Ferrum Lek
group and in 53 (80.3%) patients in Fenuls group. Targeted Hb
level (120 g/L) was achieved in 54 (81.82%) patients in Ferrum
Lek group and in 36 (54.55%) patients in Fenuls group. Drop-
outs due to adverse effects were: 1 patient in Ferrum Lek group
and 9 patients in group. Gastrointestinal adverse effects occurred
signiﬁcantly more often in Fenuls group than in Ferrum Lek
group (constipation in 21.2% and 1.5% patients, gastric com-
plaints in 28.8% and 6% respectively). The cost per achieving
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